We are a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.
Quote | Fortress Biotech Inc. (NASDAQ:FBIO)
Last: | $1.90 |
---|---|
Change Percent: | -1.07% |
Open: | $1.89 |
Close: | $1.90 |
High: | $2.05 |
Low: | $1.87 |
Volume: | 641,697 |
Last Trade Date Time: | 06/17/2024 03:00:00 am |
News | Fortress Biotech Inc. (NASDAQ:FBIO)
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106 Outpatient admini...
2024-05-17 17:13:46 ET More on Fortress Biotech Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment Seeking Alpha’s Quant Rating on Fortress Biotech Read the full article on Seeking Alpha For further details see: Fortress...
Message Board Posts | Fortress Biotech Inc. (NASDAQ:FBIO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $FBIO News Article - Checkpoint Therapeutics Announces $6.1 Million Registered Direct O | whytestocks | investorshangout | 03/31/2023 5:40:56 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation Reports Full-Year 2022 Financial Resul | whytestocks | investorshangout | 03/29/2023 8:26:10 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation to Participate in the 35th Annual ROTH | whytestocks | investorshangout | 03/07/2023 6:35:47 PM |
Has $FBIO gotten a NASDAQ warning letter yet? | Spicknspan | investorshub | 02/28/2023 12:20:02 AM |
whytestocks: $FBIO News Article - Helocyte, Inc. Announces Positive Data from Stem Cell Transplant D | whytestocks | investorshangout | 02/16/2023 7:40:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Fortress Biotech Inc. Company Name:
FBIO Stock Symbol:
NASDAQ Market:
Fortress Biotech Inc. Website:
Penny stock Mustang Bio Inc (NASDAQ:MBIO) shares are trading higher on a strong session volume of 90 million versus an average volume of 3.17 milli...
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106 Outpatient admini...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on ac...